

DOCTORAL THESIS

Organic molecules for diagnosis and therapy of Alzheimer's disease

Wang, Xueli

Date of Award:
2020

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

ABSTRACT

Alzheimer's disease has become one of the most common diseases jeopardizing the health of the human being. The main pathological feature of AD is the accumulation of A β in the brain to form senile plaques. Therefore, it is of great significance to develop new and efficient drugs targeting at amyloid- β for the detection, diagnosis and therapeutics for Alzheimer's disease.


Xanthohumol (Xn) naturally presents in hops (*Humulus lupulus* L). Studies have shown that it has anti-lipoperoxidative, anti-inflammatory, anti-proliferative activities, antiangiogenic and antioxidant effects, which further illustrates its potential therapeutic for AD. However, the bio-incompatibility and blood-brain barrier impermeability of Xanthohumol hindered its in vivo efficacy potential for treating Alzheimer's disease. Thus, we designed and prepared a series of Xanthohumol derivatives, namely, **Xn-n, (n = 1-9)** and its chalcone derivatives **C-n, (n = 1-10)** to enhance the desirable physical, biological and pharmacological properties, especially the blood-brain barrier permeability for intervention of AD.











As an effective technique for in vivo visualization, Near-infrared fluorescence imaging based on organic small molecule probes has a promising application in the diagnosis of Alzheimer's disease. However, most of the reported imaging probes can only visualize A β -plaques but do not have therapeutic potential such as neuroprotection against A β induced toxicity. Herein, we designed and synthesized a series of oligomeric A β targeted near infrared (NIR) fluorescent probes for the diagnosis and therapeutics of Alzheimer's disease, namely **DBAN-SLM, DBAN-SLOH, DBAN-OSLM** which showed remarkably effective inhibitory effect on A β aggregation, significant neuroprotection effect against the A β -induced toxicities, and suppression on A β -induced ROS










generation. indicating its great promise as a useful theragnostic agent for the early diagnosis and therapy of AD.


Dual-modal imaging is an important approach to overcome the limitations of single imaging technology in the diagnosis of AD disease. Therefore, based on the dual-modal, we designed and synthesized the NIR/MR dual-modal detection and theragnostic probes namely **Dyad-1**, **Dyad-2**, **Dyad-3** and **NP@SiO₂@F-SLOH**. More surprising is that the two NIR/MR dual-modal probes show excellent biological properties, including the ability to inhibit A β aggregation to a certain extent, neuroprotective effects on cytotoxicity caused by different forms of A β species, blood-brain barrier (BBB) permeability, and high stability.

All of these newly designed and synthesized molecules were characterized with ¹H NMR, ¹³C NMR, and HRMS and found to show good agreement with the desired structures. The photophysical properties and biological properties of these novel designed and synthesized fluorescent probe such as UV-vis absorption, fluorescence emission, dissociation constant determined by fluorescence titration, cytotoxicity assay, neuroprotection, and inhibition of A β aggregation were investigated.









$R = \text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$






TABLE OF CONTENTS

DECLARATION	i
ABSTRACT	ii
ACKNOWLEDGEMENTS	vii
TABLE OF CONTENTS	viii
LIST OF FIGURES	xv
LIST OF SCHEMES	xxx
LIST OF TABLES	xxxi
LIST OF ABBREVIATIONS AND SYMBOLS	xxxii
Chapter One The Detection of Alzheimer’s Disease and the Study of Inhibitor Based on Aβ Amyloid Peptide	1
1.1 Overview of Alzheimer's disease	1
1.1.1 Introduction	1
1.1.2 Genetic susceptibility to Alzheimer's disease	2
1.1.3 Current clinical manifestations, early diagnosis and treatment strategies for	

Alzheimer's disease	3
1.1.4 The pathogenesis of Alzheimer's disease	5
1.2 Amyloid- β ($A\beta$) Overview	6
1.2.1 Amyloid- β Processing	6
1.2.2 Clearance and degradation of $A\beta$ protein.....	7
1.2.3 Factors affecting Amyloid- β Aggregation.....	8
1.2.4 Amyloid- β Toxicity	10
1.3 Amyloid- β Detection.....	12
1.3.1 Fluorescent probe for Amyloid- β Detection	12
1.3.2 Positron Emission Tomography (PET) for $A\beta$ amyloid detection	24
1.3.3 Magnetic resonance imaging (MRI) for $A\beta$ amyloid detection	25
1.3.4 Nanoparticle fluorescent probe for $A\beta$ amyloid detection	26
1.4 Amyloid- β Inhibition.....	29
1.4.1 Small molecules, polyphenol for Amyloid- β Inhibition	30
1.4.2 Peptide for Amyloid- β Inhibition	35
1.4.3 Metal chelator for Amyloid- β Inhibition.....	37
1.4.4 Nanoparticles for Amyloid- β Inhibition.....	38

1.5 Reference.....	41
--------------------	----

Chapter Two Amyloid- β Aggregation Inhibitory and Neuroprotective Effects of Flavonoid Derivatives for Alzheimer’s Diseases 61

2.1 Introduction.....	61
2.2 Synthesis.....	66
2.3 Results and Discussion.....	69
2.3.1 Cytotoxicity of Flavonoid Derivatives.....	69
2.3.2 Studies on Neuroprotection of Flavonoid Derivatives.....	70
2.3.3 Studies on ROS Suppression of Flavonoid Derivatives.....	72
2.3.4 Studies on Intracellular Calcium Level of Flavonoid Derivatives.....	73
2.3.5 Studies on Blood-Brain Barrier Permeability of Flavonoid Derivatives .	75
2.3.6 Studies on Plasma Level of Flavonoid Derivatives	76
2.3.7 Studies on Inhibitory Effect of Flavonoid Derivatives	77
2.4 Conclusions	78
2.5 Experimental	79
2.6 Reference.....	100

Chapter Three Amyloid- β Oligomer Targeted NIR Molecular Probes for

<i>In Vivo</i> Imaging and Inhibition of Amyloid-β Aggregation	106
3.1 Introduction	106
3.2 Synthesis.....	109
3.3 Results and Discussion.....	111
3.3.1 Photophysical Properties	111
3.3.2 Fluorescence Properties with A β species	113
3.3.3 Binding studies of NIR fluorophores with A β species.....	115
3.3.4 Structure-affinity relationship analysis	122
3.3.5 Selectivity and stability of NIR fluorophore	125
3.3.6 Cytotoxicity Analysis	126
3.3.7 Studies on the Neuroprotective Effect of NIR dyes against A β_{1-42}	127
3.3.8 Studies of NIR dyes for ROS Suppression.....	128
3.3.9 Studies on the Inhibition of A β_{1-42} Aggregation.....	129
3.3.10 Studies of NIR dyes for Blood-Brain Barrier (BBB) Permeability	130
3.3.11 Studies on the Ex vivo staining of A β species in Tg brain slices.....	132
3.4 Conclusion.....	134
3.5 Experimental	135

3.6 References	144
----------------------	-----

Chapter Four Amyloid- β Targeted Gadolinium-Based NIR/MR Dual-Modal Theranostic Nanoparticles for Alzheimer’s Disease..... 149

4.1 Introduction	149
------------------------	-----

4.2 Preparation of NP@SiO ₂ @F-SLOH	151
--	-----

4.3 Results and Discussion.....	152
---------------------------------	-----

4.3.1 Characterization of NP@SiO ₂ @F-SLOH	152
---	-----

4.3.2 Cytotoxicity and Biodistribution of NP@SiO ₂ @F-SLOH	158
---	-----

4.3.3 NIR Imaging Application of NP@SiO ₂ @F-SLOH.....	161
---	-----

4.3.4 T ₁ -Weighted MR Imaging Application of NP@SiO ₂ @F-SLOH.....	166
---	-----

4.3.5 Inhibition of A β Aggregation and ROS Attenuation by NP@SiO ₂ @F-SLOH	171
--	-----

4.4 Conclusion.....	173
---------------------	-----

4.5 Experimental	174
------------------------	-----

4.6 Reference.....	182
--------------------	-----

Chapter Five Theranostic Multi-Modal Contrast Agent for Alzheimer’s Disease Mouse Model: Gadolinium (III) Complex-Cyanine Dyad 186

5.1 Introduction	186
5.2 Synthesis.....	189
5.3 Results and Discussion.....	192
5.3.1 Photophysical Properties	192
5.3.2 Fluorescence Properties with A β Species	195
5.3.3 Cytotoxicity Analysis	202
5.3.4 Studies on the Inhibition of A β Aggregation	203
5.3.5 Studies on the Neuroprotective Effect of SLN ₃ and Dyad-3 against A β ₁₋₄₂	204
5.3.6 Studies of SLN ₃ and Dyad-3 for ROS Suppression	205
5.3.7 Biodistribution of Dyad-3	206
5.3.8 Blood-Brain Barrier Permeability	208
5.3.9 Ex vivo staining of A β species in Tg brain slices	210
5.3.10 T ₁ -Weighted MR Imaging Application of Dyad-3	211
5.4 Conclusions	213
5.5 Experimental	214
5.6 Reference.....	224

Chapter Six Concluding Remarks.....	229
Appendix I ¹H NMR Spectra of Selected Novel Synthesized Compounds	232
Appendix II ¹³C NMR Spectra of Selected Novel Synthesized Compounds	244
Appendix III HRMS Spectra of Selected Novel Synthesized Compounds	256
CURRICULAM VITAE	270